Canada’s SQI Diagnostics and the University Health Network (UHN) will work together to advance the development and approval of new rapid protein assays and a point-of-care (POC) diagnostic device to help surgeons assess the viability of lungs and other organs for transplant. This could represent an important step…
Elderly patients with idiopathic pulmonary fibrosis (IPF) have high morbidity and mortality, and experience a variety of comorbidities both before and after receiving their diagnosis, a study finds. The findings of the study, “Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data,” were published in…
The U.S. Food and Drug Administration (FDA) has cleared the way for X-Rx’s idiopathic pulmonary fibrosis (IPF) therapy candidate X-165 to move into the first clinical tests. The FDA approved X-Rx’s…
Results of a Phase 2b clinical trial suggest actigraphy as a relevant tool to detect meaningful clinical changes in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) when treated with Bellerophon Therapeutics’ product INOpulse. PH-ILD includes PH patients with idiopathic pulmonary fibrosis (PH-IPF). The…
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study from the Czech Republic. The findings also revealed that a specific measure of lung function called diffusing lung capacity…
He’s a musician and a clothing designer. He’s a published author. He’s a professional scuba-diving instructor — and he has an intense passion for underwater shark photography. In fact, Noah Greenspan is anything but your typical New York pulmonary physical therapist. Since 1998, Greenspan has been running the Pulmonary Wellness…
A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic pulmonary fibrosis (IPF) patients, promoting a profibrotic environment, a study shows. Therapies that target CDH11 and break the “hug” between the two cell types may help stop this profibrotic process. The…
A large, multi-center clinical trial testing the proton pump inhibitor omeprazole as a therapy for cough in idiopathic pulmonary fibrosis (IPF) patients seems achievable and justified, according to results of a single-center pilot trial. The pilot study also suggests the need to screen large patient numbers and monitor adverse side…
The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with idiopathic pulmonary fibrosis (IPF) in South England were found to be similar to real-world data. The research confirmed the safety of both IPF therapies. The retrospective study, “South-West…
Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with Pharmaxis, may move into Phase 2 trials. Synairgen and Pharmaxis began their collaboration in 2015 to develop…
Get regular updates to your inbox.
